# Completeness Review: AIPetHealthMonitor

- **Review date:** 2026-07-18
- **Assessment basis:** Static source and configuration inspection only. Dependencies were not installed, and no build, database migration, external integration, or runtime workflow was executed.

## Classification

**Prototype-demo**

## Verdict

This is a clinical/health prototype/demo. Its 67 source files and visible routes/pages demonstrate concepts, but they do not establish durable, integrated, tested execution of the AIPet Health Monitor workflow.

## Why it is not complete

- 21 files are explicitly named as gap/backlog surfaces, so page and route counts overstate implemented product capability.
- 20 project-owned files contain direct provider/chat-completion markers; generic model calls are not a substitute for typed domain tools, grounded evidence, deterministic rules, or evaluations.
- 20 files contain mock, sample, placeholder, simulated, or random-data signals, leaving important outcomes disconnected from authoritative systems.
- No explicit schema or migration evidence was found for durable, versioned domain state.
- No recognizable project-owned automated tests were found for the primary workflow.
- No checked-in CI workflow was found to continuously verify builds, tests, migrations, and security checks.
- No environment example/template was found, leaving required configuration and secret boundaries undocumented.

## Needed features

1. Implement the Pet Health Monitor care workflow with validated observations, decisions, ownership, follow-up, and clinician-visible uncertainty.
2. Connect authoritative EHR/FHIR, laboratory/imaging, device, pharmacy, scheduling, or payer systems appropriate to the workflow, with consent and failure handling.
3. Validate clinical accuracy, calibration, contraindications, missing-data behavior, bias, and escalation on versioned representative datasets.
4. Require clinician approval, least-privilege access, consent, immutable audit, retention controls, and a clearly documented non-diagnostic boundary.
5. Replace the generated “Pharmacy Integration Medication Refills Cost Tr Page” gap surface with durable domain state, real integration behavior, explicit failure handling, and acceptance tests.
6. Add contract, integration, authorization, migration, failure-path, and end-to-end tests in CI, plus a documented nondestructive deployment/run path.

## Risks or launch blockers

- Incorrect or unreviewed output can cause patient harm.
- Health data requires strong privacy, access, retention, and audit controls.
- The root launcher can terminate unrelated processes occupying configured ports.
- The root launcher seeds, creates, migrates, or otherwise mutates database state during startup.
- The root launcher installs dependencies at run time, reducing reproducibility and expanding supply-chain risk.

## Evidence inspected

- `backend/package.json` — inspected project-owned structure or implementation evidence.
- `backend/src/index.js` — inspected project-owned structure or implementation evidence.
- `backend/src/routes/gapFeat_backend_collapses_everything_into_crud_js.js` — inspected project-owned structure or implementation evidence.
- `start.sh` — inspected project-owned structure or implementation evidence.
- `backend/src/config/database.js` — inspected project-owned structure or implementation evidence.
- `backend/package-lock.json` — inspected project-owned structure or implementation evidence.

## Recommended next action

Treat this as a prototype: prove one narrow clinical/health outcome end to end with real data, durable state, domain validation, and tests before expanding its feature catalog.

## Implementation progress

1. Implemented a consented observation-to-follow-up lifecycle with validated source versions, confidence/uncertainty, clinician ownership, approval, correction, resolution, and deletion states in policy, migration, and an authenticated owner-scoped workflow.
2. Partially implemented authoritative integrations: durable consented provider/standard operations capture idempotency, retries, receipts, failures, and reconciliation. Veterinary EHR/FHIR, lab, imaging, device, pharmacy, scheduling, and payer credentials remain closed gates.
3. Partially implemented clinical validation: durable evaluation fields cover accuracy, calibration, contraindications, missing data, bias, and escalation across species cohorts; focused tests cover uncertainty, clinical blocking, clinician approval, and deletion. Representative veterinary corpora and formal validation remain required.
4. Implemented veterinarian-only consequential approval/resolution/deletion, owner-to-pet isolation, independent review, non-diagnostic output, append-only audit, mandatory secrets, and fail-closed migration verification. Clinical consent/retention governance remains an operational gate.
5. Replaced the generated pharmacy-integration route as an execution path with durable delivery and care-case boundaries; all generated `cf-/gap-` routes are quarantined. Real pharmacy delivery remains unavailable without approved credentials and clinician workflows.
6. Implemented 6 focused tests, dependency-free CI, explicit transactional migration, read-only startup, a non-destructive launcher, and operations documentation.
